Identification

Name
Cetirizine
Accession Number
DB00341  (APRD00630)
Type
Small Molecule
Groups
Approved
Description

A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. [PubChem]

Structure
Thumb
Synonyms
  • Cetirizin
  • Cetirizina
  • Cetirizinum
Product Ingredients
IngredientUNIICASInChI Key
Cetirizine hydrochloride64O047KTOA83881-52-1PGLIUCLTXOYQMV-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CetirizineTablet20 mgOralPro Doc Limitee2016-06-13Not applicableCanada
Reactine 20mg TabletTablet20 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc2002-01-14Not applicableCanada
Rhinaris ReliefTablet20 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
ZyrtecTablet, film coated10 mg/1Oralbryant ranch prepack2008-10-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cetirizineTablet20 mgOralApotex Corporation2016-04-22Not applicableCanada
Cetirizine HydrochlorideSyrup5 mg/5mLOralSilarx Pharmaceuticals, Inc.2012-05-11Not applicableUs
Cetirizine HydrochlorideTablet5 mg/1Oralbryant ranch prepack2009-10-01Not applicableUs
Cetirizine HydrochlorideTablet10 mg/1OralH. J. Harkins Company Inc.2017-01-03Not applicableUs
Cetirizine HydrochlorideSyrup1 mg/mLOralQualitest2009-09-252016-10-13Us
Cetirizine HydrochlorideTablet10 mg/1OralDirectrx2016-12-22Not applicableUs
Cetirizine HydrochlorideSyrup1 mg/mLOralDr Reddy's Laboratories2009-08-202016-03-03Us
Cetirizine HydrochlorideSolution1 mg/mLOralPerrigo New York Inc.2008-07-24Not applicableUs
Cetirizine HydrochlorideTablet10 mg/1OralRemedy Repack2010-12-012016-10-13Us
Cetirizine HydrochlorideSolution1 mg/mLOralAidarex Pharmaceuticals LLC2013-12-03Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour AllergyTablet, film coated10 mg/1OralMeijer Distribution1997-07-07Not applicableUs
24 Hour AllergyCapsule10 mg/1OralWalgreens2013-03-01Not applicableUs
24 Hour AllergyLiquid5 mg/5mLOralMeijer Distribution2008-04-16Not applicableUs
24 Hour Allergy Lil Drug Store ProductsTablet10 mg/1OralLil' Drug Store Products, Inc.2014-11-01Not applicableUs
24-Hour All Day AllergyTablet10 mg/1OralMc Kesson2012-04-27Not applicableUs
7 Select All Day AllergyTablet10 mg/1Oral7 Eleven2014-04-29Not applicableUs
7 Select Childrens Allergy ReliefSolution5 mg/5mLOral7 Eleven2014-08-05Not applicableUs
All Day AllergyTablet10 mg/1OralHannaford Brothers Company2008-01-162017-12-22Us
All Day AllergyCapsule10 mg/1OralCardinal Health (Leader) 372052013-03-03Not applicableUs
All Day AllergySolution5 mg/5mLOralKroger2011-08-05Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
12 Hour Allergy DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralMeijer Distribution1988-07-15Not applicableUs
All day Allergy dCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralMajor2008-05-06Not applicableUs
All Day Allergy DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralHyvee2008-05-05Not applicableUs
All Day Allergy DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralKroger2014-02-19Not applicableUs
all day Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralH.E.B.2008-05-02Not applicableUs
All Day Allergy-DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralL. Perrigo Company2011-09-06Not applicableUs
Allergy and Congestion Relief D Original Prescription StrengthCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralRite Aid2008-04-10Not applicableUs
Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralPublix Supermarkets, Inc.2010-03-11Not applicableUs
Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralShopko Stores Operating2013-09-07Not applicableUs
Allergy Relief DCetirizine hydrochloride (5 mg/1) + Pseudoephedrine hydrochloride (120 mg/1)Tablet, extended releaseOralH.E.B.2018-01-19Not applicableUs
International/Other Brands
Alerlisin / Cetryn / Formistin / Hitrizin / Virlix / Zirtek / Zyrlex
Categories
UNII
YO7261ME24
CAS number
83881-51-0
Weight
Average: 388.888
Monoisotopic: 388.155370383
Chemical Formula
C21H25ClN2O3
InChI Key
ZKLPARSLTMPFCP-UHFFFAOYSA-N
InChI
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)
IUPAC Name
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
SMILES
OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication

For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria

Structured Indications
Pharmacodynamics

Cetirizine, the active metabolite of the piperazine H1-receptor antagonist hydroxyzine, is used to treat chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis.

Mechanism of action

Cetirizine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine

Volume of distribution
Not Available
Protein binding

Very high (93%) plasma protein binding

Metabolism
Not Available
Route of elimination
Not Available
Half life

8.3 hours

Clearance
  • 53 mL/min [healthy]
Toxicity

Somnolence (sleepiness or unusual drowsiness), restlessness, irritability

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Cetirizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Cetirizine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Cetirizine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cetirizine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cetirizine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cetirizine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Cetirizine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cetirizine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cetirizine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cetirizine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Cetirizine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Cetirizine.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cetirizine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Cetirizine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Azaperone.Investigational, Vet Approved
AzelastineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Cetirizine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Benzocaine.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Cetirizine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cetirizine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineCetirizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Cetirizine.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Cetirizine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Bupivacaine.Approved, Investigational
BuprenorphineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cetirizine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cetirizine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Cetirizine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Cetirizine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cetirizine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Cetirizine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cetirizine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carisoprodol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cetirizine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Cetirizine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cetirizine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Cetirizine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Cetirizine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cetirizine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cetirizine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cetirizine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cetirizine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cetirizine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Cetirizine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cetirizine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Cetirizine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Cetirizine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cetirizine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Cetirizine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cetirizine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Doxepin.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Cetirizine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Cetirizine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Cetirizine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Cetirizine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Cetirizine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cetirizine.Approved, Investigational
EthanolCetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cetirizine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cetirizine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cetirizine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cetirizine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Cetirizine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Cetirizine is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Cetirizine.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Cetirizine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Cetirizine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cetirizine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cetirizine.Approved, Investigational
HydrocodoneCetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cetirizine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Cetirizine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Cetirizine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Cetirizine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cetirizine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cetirizine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cetirizine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Cetirizine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cetirizine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cetirizine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine.Approved, Investigational
Magnesium SulfateThe therapeutic efficacy of Cetirizine can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Cetirizine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Cetirizine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Cetirizine.Investigational
MephentermineMephentermine may decrease the sedative activities of Cetirizine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cetirizine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cetirizine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Cetirizine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cetirizine.Approved
MethotrimeprazineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Cetirizine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methylphenobarbital.Approved
MetyrosineCetirizine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cetirizine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Cetirizine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Cetirizine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved, Investigational
MirtazapineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Cetirizine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cetirizine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cetirizine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Cetirizine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Cetirizine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Cetirizine is combined with Opium.Approved, Illicit
OrphenadrineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Cetirizine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cetirizine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Cetirizine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cetirizine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cetirizine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Cetirizine.Approved
ParaldehydeCetirizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cetirizine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cetirizine.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
PerazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Cetirizine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cetirizine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cetirizine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Cetirizine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Cetirizine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may decrease the sedative activities of Cetirizine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Cetirizine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Cetirizine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pomalidomide.Approved
PramipexoleCetirizine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Cetirizine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cetirizine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cetirizine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Cetirizine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cetirizine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Cetirizine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Cetirizine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Cetirizine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cetirizine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cetirizine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cetirizine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cetirizine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Cetirizine.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Romifidine.Vet Approved
RopiniroleCetirizine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ropivacaine.Approved
RotigotineCetirizine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cetirizine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cetirizine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cetirizine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sultopride.Experimental
SuvorexantCetirizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cetirizine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tetrodotoxin.Investigational
ThalidomideCetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Cetirizine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cetirizine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Cetirizine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cetirizine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Cetirizine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cetirizine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cetirizine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cetirizine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Cetirizine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Cetirizine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Cetirizine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Cetirizine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cetirizine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cetirizine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zolazepam.Vet Approved
ZolpidemCetirizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Cetirizine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cetirizine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Manne Reddy, "Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof." U.S. Patent US20040186112, issued September 23, 2004.

US20040186112
General References
Not Available
External Links
Human Metabolome Database
HMDB0005032
KEGG Compound
C07778
PubChem Compound
2678
PubChem Substance
46508368
ChemSpider
2577
BindingDB
22890
ChEBI
3561
ChEMBL
CHEMBL1000
Therapeutic Targets Database
DAP000323
PharmGKB
PA448905
IUPHAR
1222
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cetirizine
ATC Codes
R06AE07 — Cetirizine
AHFS Codes
  • 04:08.00 — Second Generation Antihistamines
FDA label
Download (54.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceChronic Prostatitis With Chronic Pelvic Pain Syndrome1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
1CompletedBasic ScienceAllergies1
1CompletedPreventionSkin Inflammation1
1CompletedTreatmentHealthy Volunteers2
1TerminatedBasic ScienceMigraines1
1, 2CompletedTreatmentNeuromyelitis Optica1
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Seasonal1
2CompletedTreatmentRhinitis, Allergic, Seasonal1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)2
3CompletedNot AvailableAllergic Rhinitis (AR)2
3CompletedTreatmentDermatitis, Eczematous / Skin Inflammation1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
3CompletedTreatmentPerennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentRhinitis, Allergic, Perennial1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)2
4CompletedNot AvailableAllergic Rhinitis (AR)1
4CompletedNot AvailableAllergies2
4CompletedNot AvailablePerennial Allergic Rhinitis (PAR) / Seasonal Allergic Rhinitis (SAR)3
4CompletedDiagnosticAsthma Bronchial1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4CompletedTreatmentAllergic Rhinitis (AR) / Pollen Allergy / Rhinitis, Allergic, Seasonal / Severe Acute Respiratory Syndrome1
4CompletedTreatmentDisseminated Sclerosis1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4CompletedTreatmentRhinitis, Allergic, Perennial and Seasonal1
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentUrticarias2
4Enrolling by InvitationTreatmentDiabetic Neuropathy, Painful / Pain, Neuropathic / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4RecruitingBasic ScienceExercise Intolerance at Altitude1
4TerminatedTreatmentPruritus1
4TerminatedTreatmentUrticarias1
4Unknown StatusTreatmentSeasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableCognition / Driving Ability / Seasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableSeasonal Allergic Rhinitis (SAR) / Sinusitis1
Not AvailableCompletedTreatmentActinic Keratosis (AK)1
Not AvailableCompletedTreatmentSeasonal Allergic Rhinitis (SAR)1

Pharmacoeconomics

Manufacturers
  • Banner pharmacaps inc
  • Actavis mid atlantic llc
  • Amneal pharmaceuticals
  • Apotex inc
  • Aurobindo pharma ltd
  • Cypress pharmaceutical inc
  • Dr reddys laboratories ltd
  • Perrigo israel pharmaceuticals ltd
  • Ranbaxy laboratories ltd
  • Sun pharmaceutical industries inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • Wockhardt ltd
  • Perrigo r and d co
  • Mcneil consumer healthcare div mcneil ppc inc
  • Caraco pharmaceutical laboratories ltd
  • Sandoz inc
  • Pfizer inc
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Cadista pharmaceuticals inc
  • Contract pharmacal corp
  • Mylan pharmaceuticals inc
  • Orchid healthcare
  • Torrent pharmaceuticals llc
  • Unichem laboratories ltd
  • Unique pharmaceutical laboratories
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
Capsule, liquid filledOral10 mg/1
Tablet, film coatedOral5 mg/1
SyrupOral1 mg/1
Tablet, film coated, extended releaseOral
SyrupOral1 mg/mL
TabletOral5 mg/1
Tablet, chewableOral10 mg/1
Tablet, chewableOral5 mg/1
Tablet, film coatedOral10 mg/1
SyrupOral5 mg/5mL
Tablet, orally disintegratingOral10 mg/1
SyrupOral5 mg
TabletOral10 mg
TabletOral5 mg
TabletOral20 mg
CapsuleOral10 mg
Tablet, chewableOral10 mg
Tablet, chewableOral5 mg
Tablet, orally disintegratingOral10 mg
SolutionOral1 mg/mL
LiquidOral5 mg/5mL
SolutionOral5 mg/5mL
Tablet, extended releaseOral
TabletOral10 mg/1
Prices
Unit descriptionCostUnit
Cetirizine HCl 100 10 mg tablet Bottle259.71USD bottle
Cetirizine HCl 100 5 mg tablet Bottle259.71USD bottle
Zyrtec 10 mg tablet2.66USD tablet
Zyrtec 5 mg tablet2.66USD tablet
Zyrtec itchy eye 0.025% drops2.62USD ml
Cetirizine hcl 5 mg chew tablet2.5USD tablet
Cetirizine hcl 10 mg tablet2.49USD tablet
Cetirizine hcl 5 mg tablet2.49USD tablet
Zyrtec-d tablet1.33USD tablet
Child's zyrtec chew tablet0.9USD tablet
CVS Pharmacy allergy relief 10 mg tablet0.74USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6469009No1999-07-132019-07-13Us
US7226614No2002-06-102022-06-10Us
US6489329No1996-04-082016-04-08Us
US7014867No2002-06-102022-06-10Us
US6455533No1998-07-022018-07-02Us
US9254286Yes2013-01-092033-01-09Us
US8829005Yes2010-09-152030-09-15Us
US9750684No2010-03-152030-03-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)112.5 °CPhysProp
water solubility101 mg/LNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0658 mg/mLALOGPS
logP2.98ALOGPS
logP0.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.6ChemAxon
pKa (Strongest Basic)7.79ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.01 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity106.87 m3·mol-1ChemAxon
Polarizability41.88 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6863
Blood Brain Barrier+0.7576
Caco-2 permeable-0.5879
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.7364
P-glycoprotein inhibitor IINon-inhibitor0.7624
Renal organic cation transporterNon-inhibitor0.5232
CYP450 2C9 substrateNon-substrate0.8408
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.8885
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9465
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6917
Ames testNon AMES toxic0.7815
CarcinogenicityNon-carcinogens0.9426
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.6841 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.866
hERG inhibition (predictor II)Inhibitor0.6517
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000j-0900000000-9801bb859e79fa9922aa
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-014b559d56b0f32984ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-213bd47e17d5ab69ad4b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004r-9006000000-f496e22c8e0e293fe98c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-d8a55ab1a7aff0580a91
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-d8a55ab1a7aff0580a91
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-dc957bb6f947575ae4fa
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000b-0900000000-48fc0581ff9fff15e16d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-04ca95fadd952d0aaeb8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0009000000-014b559d56b0f32984ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0009000000-26a7769df28c2325ec53
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0009000000-284c2e7b25733d7c9875
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0009000000-04befed283d691217ba2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-14715ff4d57580fbb166
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0069000000-431df9c3533b77cf08bc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-e042b67e2048318e7dbd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-b0dfb67717c01fd0c0b9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0970000000-e2810b242fefb4a419e7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-72f7cddc4ff6d45f98c0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-d6044767562f707c8061
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f79-0059000000-15be2621a731a6c2b0ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0090000000-01f33b4e54bcb6c8720c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-f28111ea9c76c1bd27dd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0970000000-673301f54b883df73a2a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-81ab05c275bd28fa3dfb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-82d8eb507c79b7342917
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-0f667566feb3af808386
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0690000000-0d4336539c5ebe9050c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-1638816057d01db5eaa1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-de2feb9a65604f442606
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0190000000-58d302681ca058e5706c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0391000000-7af5014f07bed862bba6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0491000000-ac48bba9129fe5016c4b

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
N-alkylpiperazines / Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Amino acids / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
Diphenylmethane / Chlorobenzene / Halobenzene / N-alkylpiperazine / Aralkylamine / Aryl halide / 1,4-diazinane / Aryl chloride / Piperazine / Amino acid
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, ether, monochlorobenzenes, piperazines (CHEBI:3561)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Christophe B, Carlier B, Gillard M, Chatelain P, Peck M, Massingham R: Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics. Eur J Pharmacol. 2003 May 30;470(1-2):87-94. [PubMed:12787835]
  3. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093]
  4. Tillement JP, Testa B, Bree F: Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol. 2003 Oct 1;66(7):1123-6. [PubMed:14505791]
  5. Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG: Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7. [PubMed:10597865]
  6. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272]

Drug created on June 13, 2005 07:24 / Updated on February 13, 2018 09:34